Can you provide the average price target for BIOCARDIA INC stock?
8 analysts have analysed BCDA and the average price target is 25.5 USD. This implies a price increase of 1892.19% is expected in the next year compared to the current price of 1.28.
BIOCARDIA INC (BCDA) Forecast, Price Target & Analyst Ratings
NASDAQ:BCDA • US09060U6064
Current stock price
1.28 USD
+0.01 (+0.79%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOCARDIA INC (BCDA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.17
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$25.50
Upside
+ 1,892.19%
From current price of $1.28 to mean target of $25.50, Based on 8 analyst forecasts
Low
$25.25
Median
$25.50
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
61.29%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for BCDA. The average price target is 25.5 USD. This implies a price increase of 1892.19% is expected in the next year compared to the current price of 1.28.
The average price target has been revised upward by 61.29% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
BCDA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BCDA.
In the previous month the buy percentage consensus was at a similar level.
BCDA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-11 | Dawson James | Downgrade | Buy -> Neutral |
| 2021-12-20 | HC Wainwright & Co. | Initiate | Buy |
| 2021-04-16 | Dawson James | Downgrade | Buy -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 1, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.17
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 30.64%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
BCDA is expected to report earnings on 4/1/2026. The consensus EPS estimate for the next earnings is -0.17 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.35M 32.35% | 477K -64.67% | 58K -87.84% | -100.00% | 8.466M | |||
| EBITDA YoY % growth | -11.82M 5.97% | -11.56M 2.20% | -7.934M 31.37% | -8.67M -9.28% | -9.996M -15.29% | -12.24M -22.45% | -8.976M 26.67% | |
| EBIT YoY % growth | -11.9M 5.78% | -11.644M 2.15% | -8.001M 31.29% | -8.295M -3.68% | -8.415M -1.44% | -10.557M -25.45% | -8.976M 14.98% | |
| Operating Margin | -881.48% | -2,441.09% | -13,794.83% | N/A | N/A | N/A | -106.02% | |
| EPS YoY % growth | -10.05 9.46% | -8.25 17.91% | N/A 61.55% | -1.17 63.02% | -0.84 28.70% | -0.82 1.83% | -0.39 52.80% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | -0.17 30.64% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | -2.346M -4.08% |
| EBIT Q2Q % growth | -1.53M 34.08% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
23.83%
EPS Next 5 Year
14.33%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
70.15%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-11.84%
EBIT Next 5 Year
-0.64%
BIOCARDIA INC / BCDA Forecast FAQ
Can you provide the upcoming earnings date for BIOCARDIA INC?
BIOCARDIA INC (BCDA) will report earnings on 2026-04-01, after the market close.
Can you provide the consensus estimates for BIOCARDIA INC next earnings?
The consensus EPS estimate for the next earnings of BIOCARDIA INC (BCDA) is -0.17 USD and the consensus revenue estimate is 0 USD.
What is the expected long term growth rate for BCDA stock?
The expected long term growth rate for BIOCARDIA INC (BCDA) is -25.99%.